Q-omics provides the consensus-scored RPL31P52 profile across patient tissues and cancer cell-line models. RPL31P52 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPL31P52 is differentially expressed in 10, with the highest sampling consensus in BRCA. Additionally, RPL31P52 RNA expression shows 15,758 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BRCA, and UVM as cancer lineages where RPL31P52 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL31P52 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL31P52 survival associations across molecular data types. RPL31P52 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL31P52 RNA expression–survival associations across cancer types. High RPL31P52 expression shows unfavorable associations in KIRC, LIHC and KICH, but favorable associations in SKCM, BLCA and READ. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPL31P52 RNA expression.
This table summarizes RPL31P52 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL31P52. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL31P52 shows lower tumor expression in BRCA and THCA and higher tumor expression in LIHC, COAD, KIRC and KICH. The BRCA box plot shows higher RPL31P52 RNA expression in normal versus tumor tissue (log2 FC = −0.371, t-test p < 0.001).
This table shows molecular features associated with RPL31P52 in patient tissues and cancer cell lines. In patient samples, RPL31P52 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
